Shares of Agilent Technologies Inc (NYSE:A) ended Friday session in red amid volatile trading. The shares closed down -0.06 points or -0.13% at $46.61 with 1.96 million shares getting traded. Post opening the session at $46.43, the shares hit an intraday low of $46.31 and an intraday high of $46.87 and the price vacillated in this range throughout the day. The company has a market cap of $15.31 billion and the numbers of outstanding shares have been calculated to be 324.38 million shares.
Agilent Technologies Inc (A) on September 22, 2016 announced the EU launch of a new CE-IVD labeled IQFISH lung cancer panel for automated analysis on Dako Omnis. The new panel enables routine pathology laboratories to easily integrate fast, high-quality FISH into their IHC workflow. This allows labs to simultaneously stain IHC and FISH slides and enable multiple FISH slides to be processed in just four hours, a process that often takes two days or more with traditional FISH.
The new panel, comprising of ALK, ROS1, RET and MET IQFISH probes, was designed using the groundbreaking, oligonucleotide-based SureFISH technology utilizing formamide-free IQFISH fast hybridization buffer.
“We are excited about the upcoming probe launches for Dako Omnis,” said Jacob Thaysen, president of Agilent’s Diagnostics and Genomics Group. “Agilent is committed to improving the speed and accuracy of patient-sample processing and the quality of test performance. We know that these factors greatly affect treatment decisions and patient outcome.”
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) ended Friday session in red amid volatile trading. The shares closed down -0.16 points or -2.05% at $7.63 with 1.95 million shares getting traded. Post opening the session at $7.78, the shares hit an intraday low of $7.55 and an intraday high of $7.94 and the price vacillated in this range throughout the day. The company has a market cap of $1.06 billion and the numbers of outstanding shares have been calculated to be 142.14 million shares.
Amicus Therapeutics, Inc. (FOLD) announced that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology in New York, NY on September 28, 2016 at 3:05pm ET.
An audio webcast of the presentation can be accessed through the Investors section of the Amicus Therapeutics corporate website at http://ir.amicusrx.com/events.cfm, and will be archived for 90 days.